On Wednesday, Guardant Health (GH) stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
↑ XThis exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Guardant Health stock is trying to complete a cup without handle with a 37.04 entry. See if the medical stock can break out in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The precision oncology company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 34%.
Guardant Health stock holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health (HIMS), Castle Biosciences (CSTL) and Quest Diagnostics (DGX) are among the top 5 highly rated stocks within the group.
YOU MAY ALSO LIKE:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。